Zofran Tablets 4mg | Medicines.ie

Home
Medicines
Zofran Tablets 4mg

Company Products

Medicine Name	Active Ingredients
Medicine Name Voltarol 50mg Gastro-resistant tablets	Active Ingredients Diclofenac Sodium
Medicine Name Voltarol Retard 100mg film-coated prolonged-release tablets.	Active Ingredients Diclofenac Sodium
Medicine Name Voltarol Retard 75mg film-coated prolonged-release tablets.	Active Ingredients Diclofenac Sodium
Medicine Name Votrient 200 mg film-coated tablets and 400mg film-coated tablets	Active Ingredients Pazopanib Hydrochloride
Medicine Name Xolair 150mg solution for injection	Active Ingredients Omalizumab
Medicine Name Xolair 75mg solution for injection	Active Ingredients Omalizumab
Medicine Name Zofran Injection 2ml	Active Ingredients Ondansetron hydrochloride dihydrate
Medicine Name Zofran Injection 4ml	Active Ingredients Ondansetron hydrochloride dihydrate
Medicine Name Zofran Suppositories	Active Ingredients Ondansetron
Medicine Name Zofran Syrup	Active Ingredients Ondansetron hydrochloride dihydrate
Medicine Name Zofran Tablets 4mg	Active Ingredients Ondansetron hydrochloride dihydrate
Medicine Name Zofran Tablets 8mg	Active Ingredients Ondansetron hydrochloride dihydrate
Medicine Name Zofran Zydis 4mg	Active Ingredients Ondansetron
Medicine Name Zofran Zydis 8mg	Active Ingredients Ondansetron
Medicine Name Zometa 4mg/100ml solution for infusion	Active Ingredients Zoledronic acid
Medicine Name Zykadia 150 mg hard capsules	Active Ingredients Ceritinib

Items Per Page :

101 - 116 of 116 items.Total: 5 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 9 September 2019 PIL

Reasons for updating

Change to section 2 - pregnancy, breast feeding and fertility

Updated on 12 April 2019 SmPC

Reasons for updating

Change to section 4.6 - Pregnancy and lactation
Change to section 4.7 - Effects on ability to drive and use machines
Change to section 5.3 - Preclinical safety data
Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 23 January 2019 PIL

Reasons for updating

Change to section 6 - marketing authorisation holder
Change to section 6 - manufacturer
Change to section 6 - date of revision

Updated on 19 July 2018 SmPC

Reasons for updating

Change to section 7 - Marketing authorisation holder
Change to section 8 - Marketing authorisation number(s)

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 15 November 2016 PIL

Reasons for updating

New PIL for new product

Updated on 15 November 2016 PIL

Reasons for updating

Change to section 3 - overdose, missed or forgotten doses

Updated on 25 August 2016 SmPC

Reasons for updating

New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 25 August 2016 SmPC

Reasons for updating

Change to section 4.9 - Overdose
Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.9 updated to include information on paediatric population.

Updated on 10 February 2016 SmPC

Reasons for updating

Change to marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change of Marketing Authorisation Holder.

Updated on 1 February 2016 SmPC

Reasons for updating

Change to section 4.1 - Therapeutic indications
Change to section 4.2 - Posology and method of administration
Change to Section 4.8 – Undesirable effects - how to report a side effect
Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.1 . Clarification to SmPC 4.1 Indications on paediatric treatment to separate adult and paediatric indications and to give age ranges for paediatric indications.
Section 4.2. Addition of ‘IV’ to Table 2 for consistency with Table 1.
Section 4.8. Update to include toxic skin eruption, including toxic epidermal necrolyis as an Undesirable Effect.
Section 4.8 Update to provide clarification on the setting of dizziness, and existing Undesirable Effect.

Updated on 28 January 2016 PIL

Reasons for updating

Change to side-effects
Change to date of revision
Change to MA holder contact details

Updated on 10 December 2015 SmPC

Reasons for updating

Change to section 4.9 - Overdose
Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.9 – Information added to the 'Symptoms and Signs and Treatment' sections of the Overdose section

Updated on 21 July 2015 SmPC

Reasons for updating

Change to section 10 - Date of revision of the text
Change to MA holder contact details

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to MA holder contact details - Address change

Updated on 20 July 2015 PIL

Reasons for updating

Change to date of revision
Change to MA holder contact details

Updated on 13 April 2015 SmPC

Reasons for updating

Change to section 4.2 - Posology and method of administration
Change to Section 4.8 – Undesirable effects - how to report a side effect
Change to section 10 - Date of revision of the text
Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.2 addition of dosing regime (spoonful)

4.8 addition of how to report an adverse event

Updated on 10 April 2015 PIL

Reasons for updating

Change to date of revision
Addition of information on reporting a side effect.

Updated on 24 February 2014 SmPC

Reasons for updating

Change to section 4.2 - Posology and method of administration
Change to section 4.3 - Contraindications
Change to section 4.4 - Special warnings and precautions for use
Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Change to section 4.9 - Overdose
Change to section 5.1 - Pharmacodynamic properties
Change to section 5.2 - Pharmacokinetic properties
Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to:

Section 4.2 - Posology and method of administration,
Section 4.3 - Contraindications,
Section 4.4 - Special warnings and precautions for use,
Section 4.5 - Interaction with other medicinal products and other forms of interaction,
Section 4.9 - Overdose,
Section 5.1 - Pharmacodynamic properties,
Section 5.2 - Pharmacokinetic properties,
Section 5.3 - Preclinical safety data

Updated on 19 February 2014 PIL

Reasons for updating

Change to drug interactions
Change to dosage and administration

Updated on 27 July 2012 SmPC

Reasons for updating

Change to section 3 - Pharmaceutical form

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to:

Section 3 - PHARMACEUTICAL FORM

4mg Film-coated tablet.

Yellow, oval, biconvex tablets “GXET3” on one face and plain on the other face.

Updated on 26 July 2012 PIL

Reasons for updating

Change to appearance of the medicine

Updated on 25 July 2012 PIL

Reasons for updating

Change to warnings or special precautions for use
Change of contraindications
Change to side-effects
Change to drug interactions

Updated on 1 June 2012 SmPC

Reasons for updating

Change to section 4.3 - Contraindications
Change to section 4.4 - Special warnings and precautions for use
Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to:

Section 4.3 - Contraindications,
Section 4.4 - Special warnings and precautions for use,
Section 4.5 - Interaction with other medicinal products and other forms of interaction,

Section 4.8 - Undesirable effects

Updated on 23 August 2011 SmPC

Reasons for updating

Change to section 2 - Qualitative and quantitative composition
Change to section 4.2 - Posology and method of administration
Change to section 4.4 - Special warnings and precautions for use
Change to section 4.7 - Effects on ability to drive and use machines
Change to section 4.8 - Undesirable effects
Change to section 5.1 - Pharmacodynamic properties
Change to section 5.2 - Pharmacokinetic properties
Change to section 5.3 - Preclinical safety data
Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to the following:

· Section 2

· Section 4.2

· Section 4.4

· Section 4.7

· Section 4.8

· Section 5.1

· Section 5.2

· Section 5.3

· Section 6.6

Updated on 18 April 2011 SmPC

Reasons for updating

Change to section 2 - Qualitative and quantitative composition
Change to section 4.4 - Special warnings and precautions for use
Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Change to section 4.6 - Pregnancy and lactation
Change to section 6.1 - List of excipients
Change to section 6.5 - Nature and contents of container
Change to section 6.6 - Special precautions for disposal and other handling
Change to section 7 - Marketing authorisation holder
Change to section 8 - MA number
Change to section 9 - Date of renewal of authorisation
Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

1. NAME OF THE MEDICINAL PRODUCT

Zofran 4mg Film-coated Tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains ondansetron 4mg as ondansetron hydrochloride dihydrate.

Excipients contain Lactose Anhydrous 81.875mg

For a full list of excipients see Section 6.1.

****************************************************************

4.4 Special Warnings and Special Precautions for Use

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT₃ receptor antagonists.

Very rarely and predominantly with intravenous Zofran, transient ECG changes including QT interval prolongation have been reported. Caution is advised if patients have recieved cardiotoxic agents and in patients with a history or family history of prolonged QT syndrome.

As Zofran is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

****************************************************************

4.5 Interaction with other medicinal products~~Medicaments~~ and other Forms of Interaction

****************************************************************

4.6 Fertility, Pregnancy and Lactation

****************************************************************

6.1 List of Excipients

Core

Lactose Anhydrous

Microcrystalline cellulose

Pregelatinised maize starch

Magnesium stearate

Film-coating

Hypromellose

Titanium dioxide (E171)

Iron oxide (E172)

****************************************************************

6.5 Nature and Contents of Container

Zofran film-coated tablets are available in ~~double foil~~ blister packs of double aluminium foil or PVC ~~comprising of a PVC/aluminium blister film~~ with aluminium lidding foil or PVC/aluminium blister film with aluminium lidding foil, containing 10 or 30 tablets.

Not all pack sizes may be marketed.

****************************************************************

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product~~Instructions for Use and Handling~~

Swallow whole with a glass of water.

****************************************************************

7. MARKETING AUTHORISATION HOLDER

GlaxoSmithKline (Ireland) Limited

Stonemasons Way,

Rathfarnham,

Dublin 16

Ireland

****************************************************************

8. MARKETING AUTHORISATION NUMBERS

~~Zofran Tablets 4mg:~~ PA 1077/16/5

****************************************************************

9. DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION

Date of first authorisation: 27^th June 1990

Date of last renewal: / 27^th June ~~2005~~2010

****************************************************************

10. DATE OF REVISION OF THE TEXT

~~January 2007~~

March 2011

Updated on 26 August 2008 SmPC

Reasons for updating

Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 May 2007 PIL

Reasons for updating

Change to side-effects

Updated on 9 March 2007 SmPC

Reasons for updating

Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 3 November 2006 PIL

Reasons for updating

Change of manufacturer

Updated on 22 July 2005 SmPC

Reasons for updating

New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 13 October 2004 PIL

Reasons for updating

New PIL for medicines.ie